These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 344288)

  • 1. A clinical evaluation of ICRF 159 as a radiosensitising agent.
    Bates T
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):127-31. PubMed ID: 344288
    [No Abstract]   [Full Text] [Related]  

  • 2. Radiotherapy combined with ICRF 159 (NSC 129943).
    Rhomberg WU
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):121-6. PubMed ID: 204615
    [No Abstract]   [Full Text] [Related]  

  • 3. Radiotherapy and ICRF 159 in the treatment of soft tissue sarcomas.
    Ryall RD
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):133-4. PubMed ID: 632140
    [No Abstract]   [Full Text] [Related]  

  • 4. Preliminary report on AT1727 as a potential radiosensitizer.
    Zhang ZY; Liu TF; Zhang XF
    Int J Radiat Oncol Biol Phys; 1984 Dec; 10(12):2305-7. PubMed ID: 6392223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical experiences with radiotherapy and ICRF 159 in sarcomas].
    Rhomberg W; Mesche E; Gefeller D; Hassenstein E
    Strahlentherapie Sonderb; 1978; 75():110-4. PubMed ID: 400195
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination of radiation and razoxane (ICRF 159) in vivo.
    Hellmann K; Grimshaw MB; Hutchinson GE
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):109-13. PubMed ID: 632139
    [No Abstract]   [Full Text] [Related]  

  • 7. Double blind controlled clinical trial of radiation plus razoxane (ICRF 159) versus radiation plus placebo in the treatment of head and neck cancer.
    Bakowski MT; Macdonald E; Mould RF; Cawte P; Sloggem J; Barrett A; Dalley V; Newton KA; Westbury G; James SE; Hellmann K
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):115-9. PubMed ID: 344287
    [No Abstract]   [Full Text] [Related]  

  • 8. Radiation as a therapeutic modality in sarcomas of the soft tissue.
    Suit H; Spiro I
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):733-46. PubMed ID: 7490238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ICRF 159, (+/-) 1,2-di(3,5-dioxopiperazin-1-yl) propane NSC-129,943; razoxane.
    Bakowski MT
    Cancer Treat Rev; 1976 Jun; 3(2):95-107. PubMed ID: 821609
    [No Abstract]   [Full Text] [Related]  

  • 10. ICRF-159 enhancement of radiation response in combined modality therapies. I. Time/dose relationships for tumour response.
    Kovacs CJ; Evans MJ; Schenken LL; Burholt DR
    Br J Cancer; 1979 May; 39(5):516-23. PubMed ID: 486307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiotherapy vs. radiotherapy and razoxane in the treatment of soft tissue sarcomas: final results of a randomized study.
    Rhomberg W; Hassenstein EO; Gefeller D
    Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1077-84. PubMed ID: 8985029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical testing of the radiosensitiser Ro-07-0582. III. Response of tumours.
    Thomlinson RH; Dische S; Gray AJ; Errington LM
    Clin Radiol; 1976 Apr; 27(2):167-74. PubMed ID: 776494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ICRF-159: current status and clinical prospects.
    Bellet RE; Rozencweig M; Von Hoff DD; Penta JS; Wasserman TH; Muggia FM
    Eur J Cancer (1965); 1977 Nov; 13(11):1293-8. PubMed ID: 590286
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of radiotherapy with and without razoxane (ICRF 159) in the treatment of soft tissue sarcomas.
    Hellmann K; Ryall RD; Macdonald E; Newton KA; James SE; Jones S
    Cancer; 1978 Jan; 41(1):100-7. PubMed ID: 414829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined treatment of lung carcinoma. Report on a prospective randomized study with radiotherapy and ICRF 159 (1,2-(3,5-dioxopiperazines-lyl)propane) (author's transl)].
    Hassenstein E; Rhomberg W
    Med Klin; 1977 Feb; 72(5):171-5. PubMed ID: 403395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment of soft tissue and osteosarcomas by radiation and ICRF 159.
    Ryall RD; Hanham IW; Newton KA; Hellmann K; Brinkley DM; Hjertaas OK
    Cancer; 1974 Oct; 34(4):1040-5. PubMed ID: 4608365
    [No Abstract]   [Full Text] [Related]  

  • 17. ICRF-159 enhancement of radiation response in combined modality therapies. II. Differential responses of tumour and normal tissues.
    Kovacs CJ; Evans MJ; Burholt DR; Schenken LL
    Br J Cancer; 1979 May; 39(5):524-30. PubMed ID: 486308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A small prospective study of chordomas treated with radiotherapy and razoxane.
    Rhomberg W; Böhler FK; Novak H; Dertinger S; Breitfellner G
    Strahlenther Onkol; 2003 Apr; 179(4):249-53. PubMed ID: 12707714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced survival with radiotherapy and razoxane compared with radiotherapy alone for inoperable lung cancer in a randomised double-blind trial.
    Newman CE; Cox R; Ford CH; Johnson JR; Jones DR; Wheaton M
    Br J Cancer; 1985 May; 51(5):731-2. PubMed ID: 3888243
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II study of ICRF-159 in refractory metastatic breast cancer.
    Creech RH; Engstrom PF; Harris DT; Catalano RB; Bellet RE
    Cancer Treat Rep; 1979 Jan; 63(1):111-4. PubMed ID: 369681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.